Clinical Trials Logo

Clinical Trial Summary

The clinical-functional result after frontal and parietal burr-hole trepanation for the treatment of chronic subdural hematoma (cSDH) is effective with regards to control of the hematoma and regression of symptoms (headache, decreased vigilance and neurological deficits). However, in patients the treatment may leave visible depressions of the scalp, just above the trepanation sites, that typically develop gradually after weeks - months after the procedure. A considerable proportion of patients find this aesthetically, functionally and psychologically disturbing; the skin depressions may even cause pain or interfere with activities of daily living, such as combing, etc. An effective method would exist to avoid this undesired treatment effect: Before the skin is closed, a permeable titanium burr-hole plate could be attached above the trepanation site in order to prevent the skin from sinking into the bony defect. However, this is rarely done today, likely because there is no evidence that this treatment modification is effective and safe. Moreover, as material is implanted, this causes additional costs. The primary aim of this study is to evaluate whether the application of burr-hole plates on both the frontal and parietal burr-hole in the context of burr-hole trepanation for the treatment of cSDH can improve patient satisfaction with the aesthetic result of the surgery. In addition, the study is intended to demonstrate that this additional measure will not result in poorer hematoma control, poorer clinical/neurological outcomes, or additional complications for the patient. In a prospective, single-blind and controlled approach, we randomize 80 patients with uni- or bilateral cSDH into an intervention group (with burr-hole plates) or into a control group (without burr-hole plates). The primary end result of the study is the patient's reported satisfaction with the aesthetic outcome of the surgical scar. Secondary results are pain, functionality, neurological status, health-related quality of life, residual hematoma volume, and complications (according to Clavien-Dindo scale; especially re-operation rate for recurring cSDH and infections). The study corresponds to a modern approach, since today's patients not only expect favorable treatment results for their disease, but the therapy should also avoid permanent undesired side-effects, if possible.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03755349
Study type Interventional
Source University of Zurich
Contact
Status Completed
Phase N/A
Start date January 29, 2019
Completion date January 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04742920 - The Onyx™ Trial For The Embolization Of The Middle Meningeal Artery For Chronic Subdural Hematoma (OTEMACS) N/A
Recruiting NCT05327933 - Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization N/A
Recruiting NCT05426889 - The Role of Meningeal Lymphatic Vessels in the Absorption of Chronic Subdural Hematoma and Its Injury Mechanism N/A
Completed NCT01930617 - Irrigation of Chronic Subdural Hematomas - is More Better? N/A
Recruiting NCT03582293 - Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma Phase 3
Terminated NCT00915928 - Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors N/A
Terminated NCT02362321 - Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma Phase 4
Recruiting NCT04573387 - Exhaustive Drainage Versus Fixed-time Drainage for Chronic Subdural Hematoma After One-burr Hole Craniostomy N/A
Withdrawn NCT03845322 - Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence Early Phase 1